HCAT is expected to report earnings to fall 73.50% to 0 cents per share on November 10
Q3'26
Est.
$0.01
Q1'26
Est.
$0.02
Q4'25
Missed
by $0.02
Q3'25
Est.
$0.06
Q2'25
Missed
by $0.63
The last earnings report on May 11 showed earnings per share of 1 cents, meeting the estimate of 1 cents. With 455.99K shares outstanding, the current market capitalization sits at 139.22M.
A.I. Advisor
published General Information
General Information
a provider of healthcare data warehousing and process improvement solutions.
A.I.dvisor indicates that over the last year, HCAT has been loosely correlated with KVYO. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HCAT jumps, then KVYO could also see price increases.
HCAT sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for HCAT moved above the 200-day moving average on August 11, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where HCAT advanced for three days, in of 245 cases, the price rose further within the following month. The odds of a continued upward trend are .
HCAT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In of 98 cases where HCAT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The 10-day RSI Indicator for HCAT moved out of overbought territory on August 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on August 07, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HCAT as a result. In of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for HCAT turned negative on August 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 48 similar instances when the indicator turned negative. In of the 48 cases the stock turned lower in the days that followed. This puts the odds of success at .
HCAT moved below its 50-day moving average on August 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HCAT crossed bearishly below the 50-day moving average on August 14, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HCAT declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.381) is normal, around the industry mean (7.217). HCAT has a moderately low P/E Ratio (0.000) as compared to the industry average of (51.063). HCAT's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (1.723). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (0.456) is also within normal values, averaging (7.001).
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. HCAT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HCAT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.
